NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Revenue History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Net Sales | ₹4,430 Cr | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr |
What is the latest Revenue of NATCO PHARMA ?
| Year | Revenue |
|---|---|
| Mar2026 | ₹4,430 Cr |
| Mar2025 | ₹3,999 Cr |
| Mar2024 | ₹2,707 Cr |
| Mar2023 | ₹1,945 Cr |
| Mar2022 | ₹2,052 Cr |
How is Revenue of NATCO PHARMA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,430 Cr | 10.77 | |
| Mar2025 | ₹3,999 Cr | 47.72 | |
| Mar2024 | ₹2,707 Cr | 39.20 | |
| Mar2023 | ₹1,945 Cr | -5.23 | |
| Mar2022 | ₹2,052 Cr | - | |
Compare Revenue of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹14,668.3 Cr | -2.8% | -14.4% | -3.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹440,278.0 Cr | -3% | -5.2% | 17.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹243,966.0 Cr | 0.2% | 9.7% | 56.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | 1.3% | 2% | 36.5% | Stock Analytics | |
| CIPLA | ₹109,950.0 Cr | -2.2% | -6.6% | -10.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,967.4 Cr | 1.4% | -3.7% | -8.8% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -2.8% |
-14.4% |
-3.2% |
| SENSEX | -2.8% |
-5.2% |
-8.4% |
You may also like the below Video Courses